Keeping Track: Shionogi, Fresenius Kabi Join July Approval Parade; Busy August Expected
Executive Summary
The latest drug development news and highlights from our US FDA Performance Tracker.
You may also be interested in...
BMS Jumps Ahead With LAG-3 Melanoma Data
LAG-3 antibody shows improved PFS when combined with Opdivo in metastatic or inoperable melanoma. Bristol Myers Squibb still awaits overall survival data but could have its second dual checkpoint inhibitor pairing.
Keeping Track: Industry Channels Inner Gottlieb As Commissioner Departs US FDA
The latest drug development news and highlights from our US FDA Performance Tracker.
Medical Aesthetics: Sales Rise For Popular Products, But Unmet Needs Remain
Botox was a game-changer, which means challengers to Allergan's blockbuster are on the way. Dermal fillers and devices also have an important role, but dermatologists say innovation is needed to fill treatment gaps. Business development is ongoing to expand companies' product portfolios.